CNCE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (5 Apr 2024 @ 04:00):

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases...

Stats
今日成交量	10.73M
平均成交量	0.00
市值	401.95M
EPS	$0 ( 2023-08-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.64
ATR14	$0.231 (2.76%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-06	Van Heek Christi	Sell	25 651	Common Stock
2023-03-06	Van Heek Christi	Sell	16 400	Common Stock
2023-03-06	Van Heek Christi	Sell	25 000	Stock Option (Right to Buy)
2023-03-06	Van Heek Christi	Sell	10 000	Stock Option (Right to Buy)
2023-03-06	Van Heek Christi	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 4 463 235

音量相关性

長: 0.24 (neutral)

短: -0.57 (weak negative)

Signal:(66.67) Neutral

Concert Pharmaceuticals 相关性

10 最正相关
NNOX	0.949
NERV	0.942
TYHT	0.942
MESA	0.94
RVNC	0.935
IDYA	0.932
PIRS	0.929
CELH	0.928
LIXT	0.928
MBINO	0.927

10 最负相关
TWKS	-0.963
FNWB	-0.958
HMST	-0.951
TCPC	-0.949
UPLD	-0.948
INFI	-0.942
EYE	-0.941
VNET	-0.94
SABRP	-0.939
TBNK	-0.938

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Concert Pharmaceuticals 相关性 - 货币/商品

0.81
( strong )

0.84
( strong )

-0.59
( weak negative )

0.62
( weak )

0.13
( neutral )

-0.41
( neutral )

Concert Pharmaceuticals 财务报表

Annual	2021
营收:	$32 578.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.00233

FY	2021
营收:	$32 578.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.00233

FY	2020
营收:	$7.90M
毛利润:	$7 902.00 (0.10 %)
EPS:	$-2.40

FY	2019
营收:	$1.08M
毛利润:	$0.00 (0.00 %)
EPS:	$-3.29

Financial Reports:

No articles found.

Concert Pharmaceuticals

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.